Could venom-derived therapeutics resolve treatment resistance in refractory EAC?
(2026) Trends in Molecular Medicine — (2026)
Files
FreuvilleLTrendsMolMed2026.pdf
Open Access - Adobe PDF
- 825.48 KB
Details
- Authors
- Abstract
- The incidence of esophageal adenocarcinoma is rising in Western countries. Despite advances in chemotherapy and immunotherapy, the prognosis remains poor, with an overall 5-year survival rate below 15%. A major challenge is the cancer's poor and often unpredictable response to current treatments. Animal venoms represent a promising yet underexplored source of therapeutic agents, offering millions of structurally diverse and highly potent bioactive peptides that can modulate a wide array of molecular targets. However, only a small fraction of these peptides has been pharmacologically characterized. This review presents the therapeutic potential of venom-derived peptides in cancer treatment, summarizes the role of ion channels in esophageal adenocarcinoma (EAC), and discusses peptides targeting ion channels that may offer new opportunities for future EAC treatment.
- Affiliations
Citations
Freuville, L., Matthys, C., Gilliaux, Q., D’Hondt, L., & Gillet, J.-P. (2026). Could venom-derived therapeutics resolve treatment resistance in refractory EAC? Trends in Molecular Medicine. Accepted/in-press. https://doi.org/10.1016/j.molmed.2026.03.007 (Original work published 2026)